thiohexam: rubber cure accelerator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7232 |
| CHEMBL ID | 1591074 |
| SCHEMBL ID | 80270 |
| MeSH ID | M0129199 |
| Synonym |
|---|
| cbs, n-cyclohexyl-2-benzothiazolesulfenamide |
| s-(1,3-benzothiazol-2-yl)-n-cyclohexylthiohydroxylamine |
| nsc4809 |
| sulfenax |
| vulcafor cbs |
| santocure powder |
| delac s |
| benzothiazyl-2-cyclohexylsulfenamide |
| conac s |
| nsc-4809 |
| curax |
| 95-33-0 |
| n-cyclohexyl-2-benzothiazolesulfenamide |
| conac a |
| accelerator cz |
| vulkacite cz |
| ekagom cbs |
| santocure pellets |
| royal cbts |
| thiohexam |
| 2-benzothiazolesulfenamide, n-cyclohexyl- |
| 2-(cyclohexylaminothio)benzothiazole |
| rhodifax 16 |
| sulfenax cb |
| sulfenamide ts |
| n-cyclohexylbenzothiazole-2-sulfenamide |
| sulfenax tsb |
| vulkacit cz |
| santocure |
| wln: t56 bn dsj csm- al6tj |
| sulfenax cb 30 |
| n-cyclohexyl-2-benzothiazole sulfenamide |
| n-(1,3-benzothiazol-2-ylthio)cyclohexanamine |
| conac h |
| brn 0192376 |
| n-cyclohexyl-2-benzothiazosulfenamide |
| 2-benzenethiazolesulfenamide, n-cyclohexyl- |
| vulkacit c |
| cyclohexyl benzothiazolesulfenamide |
| sulfenax cb/k |
| santocure vulcanization accelerator |
| vulkacit cz/c |
| pennac cbs |
| n-cyclohexylbenzothiazole-2-sulphenamide |
| accicure hbs |
| vulcafor hbs |
| ai3-16782 |
| n-cyclohexyl-2-benzothiazylsulfenamide |
| hsdb 2868 |
| soxinol cz |
| sufenax cb |
| vulkacit cz/k |
| ccris 4910 |
| einecs 202-411-2 |
| sanceler cm-po |
| nocceler cz |
| durax |
| nsc 4809 |
| NCGC00159502-02 |
| NCGC00159502-03 |
| n-cyclohexyl-2-benzothiazolylsulfenamide |
| inchi=1/c13h16n2s2/c1-2-6-10(7-3-1)15-17-13-14-11-8-4-5-9-12(11)16-13/h4-5,8-10,15h,1-3,6-7h2 |
| deqztkgfxnubjl-uhfffaoysa- |
| n-(1,3-benzothiazol-2-ylsulfanyl)cyclohexanamine |
| AKOS003658709 |
| NCGC00159502-04 |
| cas-95-33-0 |
| tox21_302924 |
| dtxsid5020360 , |
| dtxcid50360 |
| NCGC00256366-01 |
| tox21_111721 |
| tox21_202436 |
| NCGC00259985-01 |
| smr001798878 |
| MLS004773968 |
| 4-27-00-01867 (beilstein handbook reference) |
| ec 202-411-2 |
| unii-uca53g94ev |
| uca53g94ev , |
| FT-0631486 |
| n-cyclohexylbenzothiazyl-sulphenamide |
| 2-(cyclohexylaminothio)benzothiazole [hsdb] |
| cbts |
| SCHEMBL80270 |
| MLS006010082 |
| [(3as,4r,9s,10as)-2-amino-5,10,10-trihydroxy-6-imino-9-sulfooxy-3a,4,8,9-tetrahydro-1h-pyrrolo[1,2-c]purin-4-yl]methoxycarbonylsulfamic acid |
| CHEMBL1591074 |
| cyclohexylbenzothiazolylsulphenamide |
| perkacit cbs |
| sanceler cm-g |
| cyclohexyl benzothiazole sulfenamide |
| s-(1,3-benzothiazol-2-yl)-n-cyclohexylthiohydroxylamine # |
| n-cyclohexylbenzothiazoylsulfenamide |
| vulkacit cz/eg |
| banac cbs |
| n-cyclohexylbenzothiazyl sulphenamide |
| n-cyclohexyl-2-benzthiazyl sulfenamide |
| n-cyclohexyl-2-benzthiazyl sulfonamide |
| ekaland cbs |
| akrochem cbts |
| cyclohexylbenzothiazyl sulphenamide |
| vulkacit cz/eg-c |
| n-cyclohexyl-2-benzothiazyl sulphenamide |
| n-cyclohexyl-2-benzothiazolylsulfonamide |
| W-100165 |
| mfcd00022872 |
| s-(benzo[d]thiazol-2-yl)-n-cyclohexylthiohydroxylamine |
| Q4445828 |
| CS-0040170 |
| DB14200 |
| AS-15575 |
| nsc 4809; nocceler cz; accelerator cz; accicure hbs |
| BRD-K64191834-001-03-1 |
| HY-W020755 |
| E80913 |
| EN300-7402242 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " It is concluded that the No Observed Adverse Effect Levels (NOAELs) for repeat dose and reproductive/developmental toxicity are 100 mg kg-1 day-1 in this screening study." | ( Screening study for repeated dose and reproductive/developmental toxicity of rubber accelerator, N,N-dicyclohexyl-2-benzothiazolesulfenamide, in rats. Ema, M; Hirose, A; Ito, Y; Kamata, E; Matsumoto, M, 2007) | 0.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Males were dosed for a total of 44 days beginning 14 days before mating." | ( Screening study for repeated dose and reproductive/developmental toxicity of rubber accelerator, N,N-dicyclohexyl-2-benzothiazolesulfenamide, in rats. Ema, M; Hirose, A; Ito, Y; Kamata, E; Matsumoto, M, 2007) | 0.34 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 39.8107 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.9243 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID624030 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 28.1838 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 33.5255 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.7889 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 49.7540 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 44.5442 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 0.7943 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 50.2227 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 49.7520 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 25.0382 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.1075 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.5026 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 35.4120 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079; AID743080 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.3431 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 54.9410 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.7783 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 28.9612 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 2.4065 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 51.8600 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 125.4800 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 10.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 10.1156 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 6.8154 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 8.9125 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 36.1254 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 35.4813 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.9588 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 35.4813 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 29.8493 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 29.8493 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.7700 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1200929 | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fluoroalkane thioheterocyclic derivatives and their antitumor activity. |
| AID1200927 | Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fluoroalkane thioheterocyclic derivatives and their antitumor activity. |
| AID1200928 | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fluoroalkane thioheterocyclic derivatives and their antitumor activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||